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Objective: We report a case of nonimmune hydrops fetalis caused by atrial ﬂutter, which was successfully
treated by intraperitoneal and intra-amniotic injections of amiodarone.
Case Report: A 27-year-old woman presented at 30 weeks of pregnancy with hydrops fetalis caused by a
fetal atrial ﬂutter. As the transplacental passage of antiarrhythmic agents is impaired in hydrops fetalis,
we chose direct treatment using fetal intraperitoneal and intra-amniotic injections (75e300 mg) of
amiodarone. We managed to successfully convert the fetal atrial ﬂutter to normal sinus rhythm. The
woman delivered a live female baby at 33 weeks of gestation with normal sinus rhythm and neurological
development.
Conclusion: Intrauterine antiarrhythmic treatment can reduce perinatal morbidity and mortality. This
report suggests that direct fetal therapy using intraperitoneal or intra-amniotic injections of amiodarone
constitutes an effective treatment for atrial ﬂutter in cases of hydrops fetalis.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
The reported incidence of fetal tachycardia is 0.3 cases per 1000
births [1], whereas fetal atrial ﬂutter (AF) accounts for approxi-
mately one-third of fetal tachyarrhythmia [2]. Fetal tachycardia
complicated with hydrops fetalis carries a high risk of intrauterine
fetal death [3]. Therefore, if these occur before 34 weeks of gesta-
tion, intrauterine therapy is preferred to premature delivery. In
reviews of the agents used for fetal antiarrhythmic therapy, trans-
placental treatment was usually used as the ﬁrst-line treatment,
and direct fetal treatment through intramuscular, intraperitoneal,
or umbilical vein injection was left for refractory cases [4e6].
Intraperitoneal administration of antiarrhythmic drugs into the
fetal ascites has been found to be effective since its ﬁrst use by
Gembruch et al in 1988 [7,8]. According to fetal pharmacokinetics of
antiarrhythmic agents, their transplacental passage is decreased in
the presence of hydrops fetalis. We therefore chose to use amio-
darone for direct fetal therapy due to its availability and efﬁcacy in
cases of refractory arrhythmia.and Gynecology, Changhua
, Taiwan.
bstetrics & Gynecology. PublishedCase Report
A 27-year-old woman (G2P0A1) was referred to our hospital at
30 weeks of gestation for investigation and treatment of hydrops
fetalis, which had been observed at 29 weeks of gestation by her
local health care provider. Investigations for intrauterine infection
(antibody titers for toxoplasmosis, cytomegalovirus, rubella, and
parvovirus B19) were all normal. On ultrasonography, a single live
fetus with ascites, pleural effusion, and skin edema was seen. No
structural cardiac defect was noted. Fetal AF with 2:1 atrioven-
tricular block was diagnosed using M-mode echocardiography
(Figure 1A); fetal atrial and ventricular rates were approximately
480 bpm and 240 bpm, respectively. Amniotic ﬂuid index was
normal (14.74 cm). The fetus was diagnosed with heart failure
secondary to fetal AF.
As the transplacental passage of antiarrhythmic agents is
impaired in the presence of hydrops fetalis, we decided on direct
treatment using fetal intraperitoneal injection of 75 mg amiodar-
one. At 5 minutes after the ﬁrst injection into the fetal ascites,
cardioversion to normal sinus rhythm was achieved (Figure 1B).
The patient was admitted for fetal surveillance, and 0.25 mg
digoxin was administered daily. The ﬁrst cycle of betamethasone
for fetal lung maturation was given at 30 weeks. During the 4 daysby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Figure 1. (A) Fetal cardiac M-mode of a 30-week pregnancy shows atrial ﬂutter with 2:1 AV block with an atrial rate of 480 bpm and ventricular rate of 240 bpm (short arrow: atrial
beat; long arrow: ventricular beat). (B) After the ﬁrst intraperitoneal treatment at 30 weeks of pregnancy, fetal cardiac M-mode showed normal sinus rhythm. AV¼ atrioventricular;
HR¼ heart rate; FHR¼ fetal heart rate.
P.-H. Lin et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 434e436 435of hospital stay, no recurrence of fetal AF was detected. She was
discharged and received ultrasonographic follow-up every 2nd day.
At the ﬁrst outpatient department follow-up, ultrasonography
showed normal sinus rhythm and the ascites had almost dis-
appeared. At 31 weeks of gestation, a recurrence of AF was detected
on ultrasonography without progression of hydrops fetalis. Intra-
amniotic injection of 75 mg amiodarone was administered, and
cardioversion to normal sinus rhythm was observed within 5 mi-
nutes after treatment. At 32 weeks of gestation, AF was again
detected at ultrasonographic follow-up and another intra-amniotic
injection of 300 mg amiodarone was administered, with cardio-
version soon observed after treatment. The injection was repeated
after 4 days due to AF recurrence. During the 3 weeks of treatment,
AF occurred occasionally; however, hydrops fetalis improved
greatly (i.e., ascites disappeared and right pleural effusion was
minimal).
A decrease in fetal movement was observed at 33 weeks of
gestation, and a cesarean section was arranged after the patient’s
second course of betamethasone treatment. She delivered a female
baby weighing 1.76 kg with an Apgar score of 7 at 1 minute and 9 at
5 minutes. The baby had a normal sinus rhythm after delivery. She
still had mild right pleural effusion, and therefore received digoxin
and furosemide treatment for 4 days. After that, no antiarrhythmic
drug was needed. Echocardiography showed normal left ventricu-
lar function and no chamber enlargement. A thyroid proﬁle survey
was normal. The baby remained under hospital care for 24 days and
was then discharged with a body weight of 2.1 kg. She is now 4
years old and has not had any recurrence of tachyarrhythmia.
Discussion
Fetal AF is deﬁned as an atrial rate of >250 bpm with a ﬁxed
(usually 2:1) or variable atrioventricular block observed [2]. A fetus
with tachyarrhythmia without hydrops has a good prognosis aftertransplacental treatment. Jaeqqi et al [2] presented their experience
of 15 AF cases between 1988 and 1995. Eleven AF fetuses were
treated with maternal digoxin, of which four cases showed con-
version to normal sinus rhythm within 2 days of treatment and
seven still had AF at birth. They also noted that patients with
therapy-resistant AF without 1:1 atrioventricular conduction have
a good prognosis because they observed no deterioration to
hydrops. Obviously, their conclusion is not compatible with our
presenting case where we found that AF with a 2:1 atrioventricular
block could be complicated with hydrops. Furthermore, Simpson
and Sharland [9] reported that intrauterine fetal therapy for fetal
tachycardia could reduce the mortality rate of hydropic fetuses
from 56% to 9.7%. Therefore, in our presenting case involving
hydrops at 30 weeks of gestation, intrauterine therapy was
preferred to premature delivery.
The main drugs used to combat fetal antiarrhythmic therapy
are digoxin, ﬂecainide, sotalol, and amiodarone. Digoxin is used
as ﬁrst choice, followed by ﬂecainide or sotalol either alone or in
combination with digoxin. Amiodarone is usually reserved for
refractory cases [9]. The choice of drug for the ﬁrst-line treatment
of fetal tachycardia with hydrops is still controversial. Digoxin
alone is considered a poor choice for the hydropic fetus by
several studies because of low placental transfer [1,9e11], and, as
per retrospective case reviews, no antiarrhythmic agents have
shown constant efﬁcacy for hydrops. Some studies mentioned
that sotalol is an effective treatment for fetal AF and should be
considered the most successful drug in recent years [11e14].
Sotalol can cross the placenta completely with a high fetal-to-
maternal ratio (up to 1.1) [13]. In a case report, Wu et al [14]
treated AF with digoxin and sotalol for 3 weeks before delivery.
During the period of treatment, the fetal heart beat was partially
controlled with a decreased ventricular rate and no hydrops
observed. However, normal sinus rhythm was not achieved. Even
sotalol alone or combined with digoxin shows a high conversion
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maternal ratio of 0.9 in the study of Krapp et al [15]. In addition,
ﬂecainide has a good sinus conversion rate (59e95%) in treating
fetal tachyarrhythmia [4,15,16]. However, although it has a good
placental transfer ratio, ﬂecainide use was limited due to its
possible proarrhythmic effect with 14.8% mortality rate in
hydrops cases [9]. In our hospital, sotalol and ﬂecainide are not
available.
Amiodarone is considered a broad-spectrum antiarrhythmic
medication for treating many arrhythmias when other antiar-
rhythmic drugs have failed. It is easily available andwas selected for
this case. It was suggested as ﬁrst- or second-line therapy for the
treatment of fetal tachycardia by Pezard et al [1]. They suggested
daily oral administration (loading dose 1600e2400 mg daily and
maintenance dose 200e400 mg daily), and this monotherapy was
effective in ﬁve cases including two of hydropswith a rapid onset of
action at around the 5th day. One case of hydrops was caused by AF
and was converted to normal sinus rhythm after 10 days of treat-
ment. The mothers received long-term amiodarone treatment till
15e21 days before term, and there were no fetal deaths in the
amiodarone treatment group. Although transient thyroxine stim-
ulating hormone elevation was noted in six cases, only two needed
short-term thyroxine supplement. Their study suggested that
transplacental amiodarone treatment was safe and effective even in
cases of hydrops. The conclusions of this group differed from those
of earlier studies. Gembruch et al in 1989 [8] presented the ﬁrst
case of fetal supraventricular tachycardia with severe hydrops that
was successfully treated using direct repeated umbilical vein
amiodarone injections after the failure of transplacental treatment
with combined antiarrhythmic drugs. According to their experi-
ence, the dosage of umbilical vein injection should start at 2.5 mg/
kg with stepwise increments up to 5 mg/kg of estimated fetal
weight (without hydrops). In the study, they also tested the fetal
blood from the umbilical vein and detected a low placental transfer
of digoxin and amiodarone in hydrops (fetal-to-maternal transfer
in digoxin 0.2e0.4 and in amiodarone 0.015e0.028). Amiodarone
was chosen as the drug for direct fetal therapy because of its long
elimination half-life [1], which could reduce the frequency of direct
treatment.
In our presenting case, we believed that the placental transfer
of digoxin and amiodarone would be poor because of hydrops
fetalis; therefore, we selected direct therapy. Intraperitoneal and
intra-amniotic injections, but not cordocentesis, were chosen
because of their ease of use in daily practice. There were no clear
dosage guidelines to follow for these injections. According to the
guidelines for amiodarone dosage in newborns, a loading IV dose
of 25mg/kg/mine for 4 hours is followed by amaintenance dose of
4 mg/kg every 8 hours. For intraperitoneal injection, which
mimics the intravenous route, we used 75 mg amiodarone (twice
the suggested dosage of the IV route), resulting in rapid conver-
sion within 5 minutes as monitored by M-mode ultrasonography.
We noted that the AF recurred at approximately 1 week after each
injection. For the third and fourth intra-amniotic injections
(mimicking the oral route), we increased the amiodarone dosage
to 300 mg. After four direct intraperitoneal or intra-amnioticinjections, the hydrops fetalis almost resolved at delivery. No AF
or elevated thyroxine stimulating hormone level was detected in
the baby after birth. We therefore suggest that repeated intra-
amniotic amiodarone injections can be used to treat AF with
hydrops that is usually refractory to ﬁrst-line transplacental
therapy. We successfully resolved the hydrops and converted AF
rapidly at every recurrence without the need to subject the
mother to high-dose antiarrhythmic agents.
Thus, intraperitoneal or intra-amniotic amiodarone injections of
75e300 mg can be effective and safe to treat AF with hydrops
without long-term side effects. However, further clinical experi-
ence is needed to establish the dosage guidelines for the therapy.Conﬂicts of interest
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